Accelevir supports vaccine development programs by integrating molecular and immune endpoints to assess immunogenicity and efficacy.
- T-Cell Response Assays – ELISpot, ICS, and flow cytometry for Th1/Th2 balance and cytotoxic responses.
- B-Cell and Antibody Analysis – Germinal center B-cell phenotyping and antibody quantification via ELISA or neutralization assays.
- Cytokine Profiling – Multiplex Luminex platforms for innate and adaptive immune biomarkers.
- Preclinical-to-Clinical Continuity – Multi-species validated assays for translational vaccine studies.